Department of Medical Science, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, 44121 Ferrara, Italy.
Peptides. 2013 Oct;48:27-35. doi: 10.1016/j.peptides.2013.07.018. Epub 2013 Jul 30.
The pharmacological activity of the novel neuropeptide S (NPS) receptor (NPSR) ligands QA1 and PI1 was investigated. In vitro QA1 and PI1 were tested in calcium mobilization studies performed in HEK293 cells expressing the recombinant mouse (HEK293mNPSR) and human (HEK293hNPSRIle107 and HEK293hNPSRAsn107) NPSR receptors. In vivo the compounds were studied in mouse righting reflex (RR) and locomotor activity (LA) tests. NPS caused a concentration dependent mobilization of intracellular calcium in the three cell lines with high potency (pEC50 8.73-9.14). In inhibition response curve and Schild protocol experiments the effects of NPS were antagonized by QA1 and PI1. QA1 displayed high potency (pKB 9.60-9.82) behaving as a insurmountable antagonist. However in coinjection experiments QA1 produced a rightward swift of the concentration response curve to NPS without modifying its maximal effects; this suggests that QA1 is actually a slow dissociating competitive antagonist. PI1 displayed a competitive type of antagonism and lower values of potencies (pA2 7.74-8.45). In vivo in mice NPS (0.1 nmol, i.c.v.) elicited arousal promoting action in the RR assay and stimulant effects in the LA test. QA1 (30 mgkg(-1)) was able to partially counteract the arousal promoting NPS effects, while PI1 was inactive in the RR test. In the LA test QA1 and PI1 only poorly blocked the NPS stimulant action. The present data demonstrated that QA1 and PI1 act as potent NPSR antagonists in vitro, however their usefulness for in vivo investigations in mice seems limited probably by pharmacokinetic reasons.
研究了新型神经肽 S(NPS)受体(NPSR)配体 QA1 和 PI1 的药理学活性。在体外,使用表达重组小鼠(HEK293mNPSR)和人(HEK293hNPSRIle107 和 HEK293hNPSRAsn107)NPSR 受体的 HEK293 细胞进行钙动员研究来测试 QA1 和 PI1。在体内,通过小鼠翻正反射(RR)和运动活性(LA)测试来研究这些化合物。NPS 在这三种细胞系中引起浓度依赖性细胞内钙动员,具有高效力(pEC50 8.73-9.14)。在抑制反应曲线和 Schild 方案实验中,NPS 的作用被 QA1 和 PI1 拮抗。QA1 表现出高效力(pKB 9.60-9.82),表现为不可逾越的拮抗剂。然而,在共注射实验中,QA1 使 NPS 的浓度反应曲线向右迅速移动,而不改变其最大效应;这表明 QA1 实际上是一种缓慢解离的竞争性拮抗剂。PI1 表现出竞争性拮抗作用,效力值较低(pA2 7.74-8.45)。在体内,NPS(0.1 nmol,icv)在 RR 测定中引起觉醒促进作用,在 LA 测试中引起刺激作用。QA1(30 mgkg(-1))能够部分抵消 NPS 促进觉醒的作用,而 PI1 在 RR 测试中无效。在 LA 测试中,QA1 和 PI1 仅能部分阻断 NPS 的刺激作用。目前的数据表明,QA1 和 PI1 在体外作为有效的 NPSR 拮抗剂,但是由于药代动力学原因,它们在小鼠体内研究中的用途似乎受到限制。